Randall Pellish
Gastroenterology · Burlington, MANPI 1962629105
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $2,850 of the $3,211 with a category attached, or 88.8%. AbbVie accounts for 89.9% of it on its own, with 4 other manufacturers making up the rest. Reporting peaked in 2020 at $1,425 and has fallen 93.8% since, to $88 in 2025.
Across 8 payments — averaging $401.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$3K
- Boston Scientific$145
- UCB, Inc.$129
- Janssen Scientific Affairs, LLC$35
- Takeda Pharmaceuticals U.S.A., Inc.$15
Across 81 payments — averaging $1757.07 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Takeda Pharmaceuticals U.S.A., Inc.$83K
- AbbVie$59K
What the payments were for
- Speaking & faculty fees$2,85089%
- Food & beverage$36111%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 3 | $2,888 |
| Boston Scientific | 2 | $145 |
| UCB, Inc. | 1 | $129 |
| Janssen Scientific Affairs, LLC | 1 | $35 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Cimzia$129
- EXALT Model D$100
How this compares
$3,211 in reported general payments places this provider in the 65th percentile of 579 gastroenterology providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| StelaraUstekinumab | 73 | $2,036,283 |
| Humira(Cf) PenAdalimumab | 15 | $169,197 |
| Mesalamine | 34 | $24,346 |
| Balsalazide Disodium | 16 | $1,911 |
| Pantoprazole Sodium | 64 | $1,177 |
| Diphenoxylate-AtropineDiphenoxylate Hcl/Atropine | 29 | $906 |
| Lactated RingersRinger's Solution,lactated | 44 | $847 |
| LoperamideLoperamide Hcl | 15 | $668 |
| Colestipol Hcl | 13 | $595 |
| Sulfasalazine | 11 | $388 |
| Sodium Chloride0.9 % Sodium Chloride | 57 | $378 |
| Dicyclomine Hcl | 16 | $354 |
| Omeprazole | 20 | $307 |
| Prednisone | 19 | $210 |
Paid to pharmacies, not to this prescriber.
Other gastroenterology in Burlington
- Khaldoon KhirfanBurlington$167K
- Mena BakhitBurlington$54K
- Hiroyuki AiharaBoston$728K
- Jessica AllegrettiBoston$696K
- John LeungBoston$682K
- Ramnik XavierBoston$567K
- Adam CheifetzBoston$512K
- Carlo TraversoBoston$447K
- Razvan ArsenescuMedford$385K
- Steven FineFramingham$259K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.